Glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) prognosticates poor overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with androgen receptor signaling inhibitors (ARSi)
Our mission is to improve patient lives by enabling precision medicine with non-invasive tests that profile rare cells in cancer.
JUST RELEASED: AR-V7 as an indication for treatment selection
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncology. Advance Online Publication: June 4, 2016. DOI:10.1001/jamaoncol.2016.1828